Analysis Version
v1
History
Back to Study: PCSK9 stimulates Syk, PKCδ, and NF-κB, leading to ...
mechanistic
Analysis v1
Strong Support

PCSK9 doesn’t just cause inflammation — it also tricks immune cells into making more PCSK9, creating a cycle that keeps the inflammation going in artery plaques.

37
Pro
0
Against

Evidence from Studies

Supporting (1)

37

Community contributions welcome

37

PCSK9 stimulates Syk, PKCδ, and NF-κB, leading to atherosclerosis progression independently of LDL receptor

Cohort Study
Human
2024 Mar 30

The study shows that PCSK9 makes immune cells in artery plaques more inflamed by teaming up with a protein called CAP1, which matches part of the claim — even though it didn’t test if PCSK9 turns on its own production.

Contradicting (0)

0

Community contributions welcome

No contradicting evidence found

Gold Standard Evidence Needed

According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.

Source Study

PCSK9 stimulates Syk, PKCδ, and NF-κB, leading to atherosclerosis progression independently of LDL receptor

Score: 37
DOI: 10.1038/s41467-024-46336-2

Similar Assertions

Even when mice have too much PCSK9 and high cholesterol, if they have less of the CAP1 protein, their artery plaques don’t get as bad — proving CAP1 is needed for PCSK9 to cause inflammation.

37
0
78%

PCSK9, a protein in the blood, sticks to another protein called CAP1 on immune cells, which turns on a chain reaction that makes the cells more inflamed and sticky, even if cholesterol levels are normal — this can worsen artery plaque.

37
0
76%

PCSK9 doesn't just raise bad cholesterol — it also directly worsens artery disease by making immune and blood vessel cells absorb more damaged fats, reducing their ability to clean out cholesterol, and increasing inflammation in the arteries.

1
0
75%

A protein called PCSK9 causes the liver to break down fewer 'bad' cholesterol carriers, which means more of it stays in your blood.

1
0
72%

A new drug called CAP1-hFc that blocks PCSK9 from sticking to CAP1 works better at reducing inflammation in immune cells than current PCSK9 drugs like evolocumab, which only lower cholesterol.

37
0
72%